NCT01513733

The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer

The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Castration-Resistant Heavily Pre-treated Prostate Cancer

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: Andrew J. Armstrong, MD · Academic / Other
• Sex: Male
• Age: 18 Years – 79 Years
• Healthy volunteers: Not accepted

Summary

The standard of care for men with metastatic CRPC in 2010 following progression on docetaxel is cabazitaxel or abiraterone acetate/prednisone. Based on results from two other studies, cabazitaxel and prednisone has become a standard second line chemotherapy regimen and becomes the backbone upon which to improve upon. Thus, the primary objective of this study is to determine the recommended dose of tasquinimod in combination with cabazitaxel and prednisone based on safety and tolerability in men with chemorefractory metastatic castration-resistant prostate cancer (CRPC).

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
DRUG	tasquinimod	tasquinimod 0.25 mg continuously
DRUG	tasquinimod 0.25 mg; 0.5 mg	tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg continuously, if tolerated
DRUG	tasquinimod 0.25 mg; 0.5 mg; 1.0 mg	tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg for 3 weeks followed by 1.0 mg continuously, if tolerated

Timeline

• Start date: 2012-01-01
• Primary completion: 2015-06-01
• Completion: 2016-06-01
• First posted: 2012-01-20
• Last updated: 2018-09-04

Locations

2 sites across 1 country: United States